A detailed history of Gts Securities LLC transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Gts Securities LLC holds 105,500 shares of ESPR stock, worth $244,759. This represents 0.0% of its overall portfolio holdings.

Number of Shares
105,500
Previous 124,400 15.19%
Holding current value
$244,759
Previous $276,000 36.96%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$1.61 - $2.73 $45,717 - $77,521
28,396 Added 26.51%
135,505 $223,000
Q2 2024

Aug 14, 2024

BUY
$1.84 - $3.24 $60,191 - $105,990
32,713 Added 43.97%
107,109 $237,000
Q1 2024

May 15, 2024

BUY
$2.02 - $3.02 $95,517 - $142,803
47,286 Added 174.42%
74,396 $199,000
Q4 2023

Feb 14, 2024

BUY
$0.73 - $3.08 $9,477 - $39,987
12,983 Added 91.9%
27,110 $81,000
Q3 2023

Nov 15, 2023

BUY
$0.96 - $1.79 $13,561 - $25,287
14,127 New
14,127 $13,000

Others Institutions Holding ESPR

About Esperion Therapeutics, Inc.


  • Ticker ESPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,551,600
  • Market Cap $154M
  • Description
  • Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...
More about ESPR
Track This Portfolio

Track Gts Securities LLC Portfolio

Follow Gts Securities LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gts Securities LLC with notifications on news.